N4 Pharma Plc

We are pleased to announce that our oral Inflammatory Bowel Disease (IBD) product, N4 101, has undergone a series of in vitro experiments which demonstrate the benefits of Nuvec® delivery technology where other approaches struggle.   These include: functionality to target specific cells; protecting the payload from enzyme degradation, allowing oral delivery to the gut; and loading multiple RNA therapeutics onto the same particle.   Read the full update for comments from our CEO, Nigel Theobald, and to discover the methodologies used: https://lnkd.in/g7kGCVnC

Dr. David Templeton, Technical Director at N4 Pharma, explores the critical need to invest in oral treatments for Inflammatory Bowel Disease (IBD), including the development of effective oral delivery systems for inflammation inhibitors, in our new article published in International Pharmaceutical Industry.   As research advances in uncovering the causes of IBD, targeted oral treatments offer a promising opportunity for better disease management and patient outcomes.   We believe that the next generation of IBD treatments will depend on improved delivery technologies, such as Nuvec.   Read the article here to learn more: https://lnkd.in/ecM-qhNs

N4 Pharma Plc has now filed a new patent for its oral anti-inflammatory IBD product, N4 101.   The orally delivered product uses Nuvec® to target the cells that cause inflammation in patients with Irritable Bowel Disease (IBD) - inhibiting the production of TNF-alpha and promoting the body's natural anti-inflammatory defences.    Nigel Theobald, CEO N4 Pharma adds "By filing the patent, we are now able to talk to our investors and potential collaborators about our product and will shortly provide an update on the 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 work we have completed."    For more information, including a video by Nigel, and to submit any questions, please visit the N4 Pharma investor hub: https://lnkd.in/eDTuiDWP   #IBD #patent #drugdelivery #diseasehttps

Exciting to see that Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a new licensing agreement focused on RNAi therapies. Arrowhead started out as a platform company and will license its clinical-stage assets developed using the company's platform to Sarepta: https://lnkd.in/ekYhMzY3   As well as the deal boosting Sarepta's pipeline in rare diseases, it provides Arrowhead with the financial runway to advance its later-stage drug candidates.    Like Arrowhead, N4 Pharma Plc is using its innovative siRNA targeting delivery systems Nuvec® and LipTide® to develop its two lead programmes N4101 and ECP105. For more information check out our new corporate presentation: https://lnkd.in/e-n7C7cb   #pharma #collaboration #biotech #drugdiscovery 

The Human Cell Atlas project aims to map all 37 trillion cells in the human body, with the potential to revolutionise our understanding of how the human body functions and diseases develop.   Amongst its latest discoveries the project has revealed a new cell form, the gut metaplastic cell, which is linked to exacerbating inflammation in individuals that live with inflammatory bowel diseases.   As scientific knowledge of human cells improves, treatments that can target specific cell types through technologies, such as Nuvec®, will become more in demand.   Read the article from BBC News to learn more about the exciting milestone findings from this innovative project which is enhancing scientists’ understanding of the human body: https://lnkd.in/eSCsXy23   #IBD #cell #disease

Join N4 Pharma Plc at Mello2024 for the 10th year of Mello Events' premier investor event at Derby Conference Centre. Our CEO Nigel Theobald will be speaking at the conference on Tuesday 19th November at 4:10pm in the Cavendish room and will present N4 Pharma's strategic focus on its two key lead programs: N4 101 for #IBD and ECP 105 for prevention of post-surgical scarring following #glaucoma treatment. If you haven't already got your tickets, visit: https://lnkd.in/eN-ypXWB

Join our growing shareholder community on the N4 Pharma Investor Hub! This month we released our updated corporate presentation alongside a video from CEO Nigel Theobald, and we've been engaging with our investor base through their questions on the hub. Sign up to get updated on N4 Pharma news and ask us anything! https://lnkd.in/eRNh6cC9

📢 Investor Q&A Session now LIVE – N4 Pharma Plc CEO Nigel Theobald recently addressed key investor questions following our latest corporate presentation: https://lnkd.in/eegWhpEc Nigel covers topics including: 1️⃣ Company Valuation: Why he believes N4 Pharma is undervalued and the potential market positioning. 2️⃣ Data Sharing and Updates: Plans for progress updates on N4 101 and other projects. 3️⃣ Collaboration Development: Insights into potential partnerships, especially after the SRI collaboration. 4️⃣ Orphan Drug Designation (ODD): Potential impact for ECP 105 if ODD isn’t granted. 5️⃣ Upcoming Milestones: What’s next for N4 Pharma and the expected market impact. Dive into the full Q&A to get the latest insights and stay informed on N4 Pharma’s journey. Submit any further questions here: https://lnkd.in/eegWhpEc

Our CEO Nigel Theobald shares his insight into 'the one thing that could dramatically improve the #pharma industry as we know it' with The Medicine Maker, emphasising the importance of government support and investment in small #biotech companies, which he believes could significantly enhance innovation and efficiency within the sector. Find out why, according to Nigel, "the traditional pharma model is no longer fit for purpose and needs a dramatic overhaul" here: https://lnkd.in/eFp9J_s3

We have developed a new corporate presentation outlining our strategic focus on N4 Pharma's two lead programs: N4 101 for Irritable Bowel Disease (IBD) and ECP 105 for post-surgical scarring prevention. Watch the video update from our CEO, Nigel Theobald here: https://lnkd.in/e-n7C7cb